191 related articles for article (PubMed ID: 32526041)
1. LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations.
Brar N; Butzmann A; Kumar J; Peerani R; Morgan EA; Grigoriadis G; Kumar B; Tatarczuch RM; Warnke RA; Ohgami RS
Histopathology; 2020 Dec; 77(6):984-988. PubMed ID: 32526041
[TBL] [Abstract][Full Text] [Related]
2. T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker.
Zanelli M; Loscocco GG; Sabattini E; Zizzo M; Sanguedolce F; Panico L; Fanni D; Santi R; Caprera C; Rossi C; Soriano A; Cavazza A; Giunta A; Mecucci C; Vannucchi AM; Pileri SA; Ascani S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205834
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of LMO2 immunohistochemistry in distinguishing T-lymphoblastic leukemia/lymphoma from thymoma.
Bansal D; Pasricha S; Gupta G; Sharma A; Durga G; Kamboj M; Mehta A
Indian J Pathol Microbiol; 2024; 67(1):141-144. PubMed ID: 38358204
[TBL] [Abstract][Full Text] [Related]
4. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
5. Indolent T-lymphoblastic proliferation concomitant with acinic cell carcinoma mimicking T-lymphoblastic lymphoma: case report and literature review.
Yasuda H; Tsutsui M; Ota Y; Tanaka M; Komatsu N
Histopathology; 2018 Apr; 72(5):862-866. PubMed ID: 29143359
[TBL] [Abstract][Full Text] [Related]
6. sTRBC1 and cyTRBC1 Expression Distinguishes Indolent T-Lymphoblastic Proliferations From T-Lymphoblastic Leukemia/Lymphoma.
Liu J; Li M; Fu J; Dong M; Fan X; Zhong L; Xu G; Li Y; Xi Q
Am J Surg Pathol; 2023 Nov; 47(11):1325-1331. PubMed ID: 37515427
[TBL] [Abstract][Full Text] [Related]
7. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
[TBL] [Abstract][Full Text] [Related]
8. Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma.
Ohgami RS; Arber DA; Zehnder JL; Natkunam Y; Warnke RA
Adv Anat Pathol; 2013 May; 20(3):137-40. PubMed ID: 23574769
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric features of incidental indolent T lymphoblastic proliferations.
Fromm JR; Edlefsen KL; Cherian S; Wood BL; Soma L; Wu D
Cytometry B Clin Cytom; 2020 May; 98(3):282-287. PubMed ID: 31571375
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.
Miyashita K; Kitajima K; Goyama S; Kitamura T; Hara T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2310-2316. PubMed ID: 29278703
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.
Menter T; Gasser A; Juskevicius D; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):491-8. PubMed ID: 25203428
[TBL] [Abstract][Full Text] [Related]
12. Indolent T-lymphoblastic proliferation with fibrolamellar hepatocellular carcinoma developed after colorectal adenocarcinoma: a case report.
Han W; Wang B; Yong X; Zhang Y; Shao M; Wang C
Pathol Oncol Res; 2023; 29():1611151. PubMed ID: 37252318
[No Abstract] [Full Text] [Related]
13. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
[TBL] [Abstract][Full Text] [Related]
14. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.
Latchmansingh KA; Wang X; Verdun RE; Marques-Piubelli ML; Vega F; You MJ; Chapman J; Lossos IS
Mod Pathol; 2022 Sep; 35(9):1220-1226. PubMed ID: 35322192
[TBL] [Abstract][Full Text] [Related]
15. Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
Shields BJ; Alserihi R; Nasa C; Bogue C; Alexander WS; McCormack MP
Leukemia; 2015 Apr; 29(4):927-38. PubMed ID: 25283843
[TBL] [Abstract][Full Text] [Related]
16. Indolent T-lymphoblastic proliferation: a report of three cases.
Yuanyuan Z; Jianlan X; Yanlin Z; Xiaoge Z
Virchows Arch; 2022 May; 480(5):1121-1126. PubMed ID: 34482472
[TBL] [Abstract][Full Text] [Related]
17. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous involvement in lymphoblastic lymphoma.
Chimenti S; Fink-Puches R; Peris K; Pescarmona E; Pütz B; Kerl H; Cerroni L
J Cutan Pathol; 1999 Sep; 26(8):379-85. PubMed ID: 10551409
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of anti-terminal deoxynucleotidyl transferase antibody (TdT) in hematologic pathology].
Valmary S; Danjoux M; Delsol G; Brousset P
Ann Pathol; 2005 Feb; 25(1):25-32. PubMed ID: 15981929
[TBL] [Abstract][Full Text] [Related]
20. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
